How to Buy Axsome Therapeutics Stock
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States.
Axsome Therapeutics stock last closed at $233.80, down 6.09% from the previous day, and has increased 111.14% in one year. It has overperformed other stocks in the Biotechnology industry by 0.95 percentage points. Axsome Therapeutics stock is currently +143.31% from its 52-week low of $96.09, and -10.14% from its 52-week high of $260.19.
At the moment, there are 51.46M shares of AXSM outstanding. The market cap of AXSM is $12.03B. In the last 24 hours, 786,000 AXSM shares were traded.
How to Buy Axsome Therapeutics Stock
Not sure how to invest in Axsome Therapeutics stock? Here's how.
- Choose where to buy Axsome Therapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Axsome Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Put funds into your investment account: Pick your method of payment and add your details.
- Evaluate Axsome Therapeutics stock: The Axsome Therapeutics ticker symbol is AXSM. Is Axsome Therapeutics stock a good investment? Should you buy shares of AXSM? How do AXSM's underlying business fundamentals look? Do top analysts think Axsome Therapeutics is a good buy? Why has AXSM's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if AXSM is a good stock to buy).
- Make your AXSM purchase: Decide if you will purchase AXSM shares at the current market price or use a limit order to buy AXSM shares at a particular price.
- Monitor your AXSM investment: Create a watchlist to keep track of your investment in Axsome Therapeutics stock.
Step 1: Choose where to buy Axsome Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy AXSM stock.
Our recommended brokerage: eToro
We believe that eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal information so you can invest in AXSM stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start a new brokerage account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have opened your account on the highest rated stock app, you need to deposit funds:
Check out this video walkthrough to see the process of transferring funds into your new investment account.
Step 4: Evaluate Axsome Therapeutics stock
Once you have identified the best place to buy Axsome Therapeutics stock, it's critical to analyze their stock before you buy, so you can understand the risk and upside.
Axsome Therapeutics quick stats
AXSM Due Diligence Checks
WallStreetZen was built to help everyday investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on AXSM's stock page.
Is AXSM stock overvalued?
You can use many financial metrics, analyses, models, and charts to gauge AXSM's fair value.
Using relative valuations ratios:
- AXSM may be overvalued based on its P/B ratio of 220.41x, relative to Biotechnology industry P/B ratio of 5.52x
You can do additional valuation research on AXSM's stock here.
Is AXSM a healthy company?
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the AXSM balance sheet.
- There are more short-term assets than long-term liabilities on the AXSM balance sheet.
- AXSM has cash burn of 70993000. It has enough cash and short-term investments to cover this for at least one year.
- AXSM has $305.11M in cash and short term investments. This is sufficient to cover its annual cash burn of $70.99M.
Negative Health Checks:
- Total AXSM debt is higher than 5 years ago, relative to shareholder equity.
- AXSM has a relatively high debt to equity ratio of 12.07.
- AXSM profit margin has gone up by 0.38 percentage points in the past year, but the company is still unprofitable.
Do analysts think it's a good time to buy Axsome Therapeutics stock
Out of 14 Wall Street analysts who give forecasts on AXSM, the consensus analyst rating on Axsome Therapeutics is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent AXSM Analyst Upgrades/Downgrades
Yatin Suneja, a top 2% analyst from Guggenheim maintains AXSM with a strong buy rating and raises their AXSM price target from $245.00 to $260.00, on May 5, 2026.
Guggenheim's Yatin Suneja raised their price target on Axsome Therapeutics (NASDAQ: AXSM) by 6.1% from $245 to $260 on 2026/05/05. The analyst maintained their Strong Buy rating on the stock.
Axsome Therapeutics reported its Q1 2026 earnings.
Following an assessment of the print, Suneja cited the following factors for their price target hike:
- Continued strong product performance.
- A growing pipeline with multiple near-term catalysts.
- Sufficient capital to fund operations into cash flow positivity.
Earnings Report
For Q1 2026, Axsome Therapeutics reported:
- EPS of $(1.26), which missed the Zacks Consensus Estimate of $(0.85) and Q1 2025's $(0.80).
- Revenue of $191.2M, which beat the Zacks Consensus Estimate by 1.04% and Q1 2025's $121.46M.
Management did not provide revenue or earnings guidance in its press release.
CEO Herriot Tabuteau, MD, commented: “Axsome had a tremendous start to 2026.
"Our commercial business delivered robust year-over-year growth in the first quarter, Auvelity was approved by the FDA as a first-in-class medicine for the treatment of agitation associated with dementia due to Alzheimer’s disease, and we added a potentially first-in-class Phase 3-ready PDE10A inhibitor for schizophrenia and Tourette syndrome to our pipeline.
“The approval of Auvelity for Alzheimer’s disease agitation highlights our research and development productivity and commitment to deliver innovation to patients living with serious brain health disorders.
"With three differentiated marketed medicines now approved for four highly prevalent CNS conditions, and an innovative pipeline which includes six potentially first-in-class and best-in-class product candidates targeting ten conditions with significant unmet medical need in psychiatry and neurology, Axsome is positioned to advance the frontiers of brain health for patients, and deliver substantial value for shareholders.”
Graig Suvannavejh, a top 6% analyst from Mizuho maintains AXSM with a buy rating and raises their AXSM price target from $228.00 to $310.00, on May 5, 2026.
Joel Beatty, a top 5% analyst from Baird maintains AXSM with a buy rating and raises their AXSM price target from $241.00 to $246.00, on May 5, 2026.
Ami Fadia, a top 1% analyst from Needham maintains AXSM with a buy rating and raises their AXSM price target from $255.00 to $267.00, on May 5, 2026.
Andrew Tsai, a top 18% analyst from Jefferies maintains AXSM with a strong buy rating and raises their AXSM price target from $245.00 to $275.00, on May 4, 2026.
You can dive deeper into what analysts are forecasting on the Axsome Therapeutics stock forecast page.
AXSM Technicals
Is AXSM Growing Revenue?
Last year, AXSM revenue was $708.24M. During the last three year, AXSM's revenue has increased by 157.37% per year. This was faster than the Biotechnology industry average of 31.34%.
Learn more about AXSM's earnings and revenue performance here.
Latest Insiders Trades at AXSM
In the past year, insiders at AXSM have sold more shares than they have bought.
Herriot Tabuteau, Chief Executive Officer of AXSM, was the latest AXSM insider to buy. They bought $245,846.70 worth of AXSM shares on Jul 1, 2026.
Learn more about who owns AXSM shares here.
Does AXSM stock generate passive income?
No, Axsome Therapeutics doesn't provide an income stream by paying out dividends.
AXSM Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your AXSM purchase
There are two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually the best for newer investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given dollar amount, use a limit order.
Hit the Open Trade button and your broker will execute your order.
If you require more info about investing in stocks on eToro, click the how to video below:
Step 6: Monitor your AXSM investment
Now that you own some shares in AXSM, you'll want to keep up with your new stock purchase.
Make a watchlist to keep tabs on your AXSM stock.
AXSM Feed
How to Buy Stock in Axsome Therapeutics
To reiterate, here are the 6 steps for buying Axsome Therapeutics stock:
- Choose where to buy Axsome Therapeutics stock
- Open your brokerage account
- Put funds into your investment account
- Evaluate Axsome Therapeutics stock
- Make your AXSM purchase
- Monitor your AXSM investment
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep an eye on your investment in Axsome Therapeutics, add AXSM to your watchlist below.
More Stock Buying Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.